Skip to Late-Breaking Abstracts »

All accepted abstracts are available in the Journal for ImmunoTherapy of Cancer (JITC).

Abstract Titles

Poster Presentation Dates

All odd numbered posters will be presented on Wednesday, Nov. 11, from 5:15-5:45 p.m. EST and Friday, Nov. 13, from 4:40-5:10 p.m. EST. Even numbered posters will be presented on Thursday, Nov. 12, from 4:50-5:20 p.m. EST and Saturday, Nov. 14, from 1-1:30 p.m. EST.

Posters will be on display from 8 a.m. on Monday, Nov. 9, until the virtual poster hall closes on December 31, 2020.


Search word or phrase:

# Type Title Authors Category Keywords
426 Poster Presentation MK-3475-U02: Phase 1/2 study of investigational agents with or without pembrolizumab versus pembrolizumab monotherapy in melanoma Reinhard Dummer, MD; Georgina V. Long, BSc, PhD, MB, BS, FRACP; Anna Pavlick, DO; Michael Postow, MD; Antoni Ribas, MD, PhD; Caroline Robert, MD, PhD; Richard A. Scolyer, BMedSci, MBBS, MD, FRCPA, FRCPath; Janis M. Taube, MD; Michael Tetzlaff, MD, PhD; Jason Liao, PhD; Sama Ahsan, MD; Scott J. Diede, MD, PhD; Hussein A. Tawbi, MD, PhD; In-Progress Clinical Trials Checkpoint blockade; Clinical trial; Solid tumors; Targeted therapy
429 Poster Presentation Long-term analysis of MASTERKEY-265 phase 1b trial of talimogene laherparepvec (T-VEC) plus pembrolizumab in patients with unresectable stage IIIB-IVM1c melanoma Georgina V. Long, MBBS, PhD, BSc, FRAC; Reinhard Dummer, MD; Douglas B. Johnson, M.D.; Olivier Michielin, MD PhD; Salvador Martin-Algarra; Sheryl A. Treichel; Edward L. Chan; Scott J. Diede, MD, PhD; Antoni Ribas, MD, PhD; In-Progress Clinical Trials Antibody; Checkpoint blockade; Clinical study; Clinical trial; Solid tumors; Targeted therapy
432 Poster Presentation 3-year results of the phase 2 randomized trial for talimogene laherparepvec (T-VEC) neoadjuvant treatment plus surgery vs surgery in patients with resectable stage IIIB-IVM1a melanoma Reinhard Dummer, MD; David E. Gyorki; John Hyngstrom, MD; Adam C. Berger, FACS, MD; Robert M. Conry, MD; Lev Demidov, MD, DSc; Edward L. Chan; Hoi-Shen Radcliffe; Mark B. Faries, MD; Merrick Ross, MD; In-Progress Clinical Trials Clinical trial; Solid tumors; Surgery